A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally

(2023) Sho Kawashima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries

(2023) Carmen Flores-Pérez et al.   Pharmaceutics

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

(2023) Ryosuke Shimizu et al.   CLINICAL DRUG INVESTIGATION

A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

(2023) Hiroshi Yotsuyanagi et al.   MEDICINE

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model

(2023) Keita Fukao et al.   Viruses-Basel

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

(2022) Yuto Unoh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

(2022) Ryuta Uraki et al.   NATURE

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

(2022) Hiroshi Mukae et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

(2022) Ryosuke Shimizu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

(2022) Hiroshi Mukae et al.   CLINICAL INFECTIOUS DISEASES

Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

(2016) Katherine L. Gill et al.   CLINICAL PHARMACOKINETICS

Age-Related Changes in Pharmacokinetics

(2011) Shaojun Shi et al.   CURRENT DRUG METABOLISM

Exploring Differences in Drug Doses Between Japan and Western Countries

(2010) F L Arnold et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS